ArticleJournal for immunotherapy of cancer2022

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment.

Elisabetta Gambale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.